The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients

Marco Vicenzi, Roberta Di Cosola, Massimiliano Ruscica, Angelo Ratti, Irene Rota, Federica Rota, Valentina Bollati, Stefano Aliberti, Francesco Blasi

Please cite this article as: Vicenzi M, Di Cosola R, Ruscica M, et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. Eur Respir J 2020; in press (https://doi.org/10.1183/13993003.01157-2020).

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Title: The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients

Marco Vicenzi1,2, Roberta Di Cosola2, Massimiliano Ruscica3, Angelo Ratti2, Irene Rota1, Federica Rota4, Valentina Bollati4, Stefano Aliberti5,6, Francesco Blasi5,6

1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Cardiovascular Disease Unit, Internal Medicine Department, Milan, Italy; 2 Dyspnea Lab, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 3 Department of Pharmacological and Biomolecular Science, University of Milan, Milan, Italy; 4 EPIGET Lab, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 5 University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy; 6 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy.

Corresponding author:
Marco Vicenzi
marco.vicenzi@unimib.it
University of Milan
Department of Clinical Sciences and Community Health
Cardiovascular Disease Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Via Francesco Sforza, 35
20122 Milan, Italy
T +39 02 50320512
Introduction

Expanding from China around the World, COVID-19 is the disease caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2). COVID-19 primarily manifests by hypoxic normo-hypocapnia with preserved lung compliance [1]. In the absence of targeted treatment, sub-intensive clinicians support patients with non-invasive ventilation and anti-inflammatory/anti-viral agents waiting for status improvement. Angiotensin-converting enzyme 2 (ACE2), highly expressed on the external membrane of lungs, heart, kidney and gastrointestinal tract cells, displays the binding site for the spike protein of SARS-CoV-2 [2]. ACE2, identified as counterpart of the Renin-Angiotensin-Aldosterone System (RAAS), converts Angiotensin (Ang) II to Ang-(1-7) and Ang I to Ang-(1-9). ACE2 activity induces vasodilatation and reduces cell growth and inflammatory response. In experimental models that mimic the viral acute respiratory distress syndrome (ARDS), the absence of Ace2 led to inflammation, vascular permeability and lung injury via activation of Ang II pathway [3, 4]. The decrease in ACE2 activity by SARS-CoV-2 can unleash a cascade of injurious effects through a heightened imbalance in the actions of the products of ACE vs ACE2. Moving to a clinical setting, the ACE2 downregulation may be one of the pathways sustaining arterial hypertension [5] and pulmonary arterial hypertension [6]. Therefore, it is conceivable that in COVID-19 a cleavage of membrane ACE2 along with its circulatory levels could impact on the disease progression and clinical worsening [7]. Thus, to support a pathophysiologial role of ACE2, the present report shares clinical data from an observational study conducted on 40 patients with a diagnosis of COVID-19, hospitalized in the Cardiorespiratory Sub-Intensive COVID-19 Unit at the Fondazione IRCCS Ca’ Granda Policlinico Hospital of Milan.

Methods

Forty consecutive patients with COVID-19 were recruited. At that time, standardized treatment was hydroxychloroquine and lopinavir/ritonavir. Blood pressure (BP), partial pressure of oxygen and inspiratory fraction of oxygen ratio (PaO₂/FiO₂) and alveolar-arterial oxygen gradient (ΔA-aO₂) were measured 2 to 4 times/day according to standard clinical protocol. Median value of plasma potassium concentration ([K⁺]plasma) was also evaluated. In the case of any supplementation of potassium, or administration of mineralcorticoid receptor antagonists or diuretic stimulators, the [K⁺]plasma we considered was referred prior to the pharmacological intervention. The relationship between respiratory and hemodynamic variables, i.e. ΔA-aO₂ vs meanBP was evaluated by Poon’s analysis which allows to normalize the inter-individual variability [8]. The composite of death and invasive ventilation were evaluated after 28 days of hospitalization.

Results

Mean age was 64±11 years and twenty-nine out of forty patients were male. All patients had normal heart function, but one had stable heart failure with reduced ejection fraction. Despite only 23 patients presented with a pre-existing history of hypertension (preHT), all patients, although under optimized non-invasive ventilatory treatment (optimal FiO₂ and positive end-respiratory pressure), showed a degradation of PaO₂/FiO₂ and ΔA-aO₂ concomitant with a raised BP and average drop in [K⁺]plasma (figure, Panel A-B-C-D). [K⁺]plasma median was 3.8 mmol/L. The median time period leading to a negative clinical picture was 4.25 days. According to hemodynamic and respiratory changes, patients were grouped as follows: group 1 (8/40 patients, 4/8 with preHT) and group 2 (32/40
patients, 15/32 with preHT). Group 1 showed temporary oscillations towards high BP with contrary changes in lung function (best vs worst status: PaO₂/FiO₂=311 vs 130 mmHg; ΔA-aO₂=107 vs 312 mmHg; meanBP=83 vs 89 mmHg). After 28 days, these patients showed better outcomes, i.e. no deaths and clinical improvement, even after the need of invasive ventilatory support (2 cases). Patients in group 2 were in critical disease (best status: PaO₂/FiO₂=286 mmHg; ΔA-aO₂=158 mmHg; meanBP=88 mmHg). They experienced a rapid deterioration of clinical conditions with linear increasing of BP and progressive worsening in gas exchange (worst status: PaO₂/FiO₂=122 mmHg; ΔA-aO₂=364 mmHg; meanBP=111 mmHg). Panel E shows a positive correlation between ΔA-aO₂ and meanBP as assessed by Poon’s analysis (slope= 6.666, R²=0.757; p< 0.0001). According to our hypothesis, [K+]plasma was considered as marker of RAAS activation and in group 2 the median value of 3.8 mmol/L was used to stratify the patients. The slope of ΔA-aO₂/meanBP relationship was significantly (U Test, p<0.001) stepper in those with [K+]plasma <3.8 mmol/L (see grey dots of panel F). After 28 days, compared to group 1, those in group 2 had a greater prevalence of intensive care need (6/32) and a higher mortality (16/32) in a very short period time (6.1 days). At the date of April 12th, the remaining 10 patients were still alive or discharged at home.

**Discussion**

Our findings showed that in COVID-19 a degradation of lung function may be associated with a rise in BP. Though COVID-19 is primarily known as a respiratory disease, it seems to move progressively to a vascular disease resulting in a hemodynamic instability. In line with the evidence that SARS-CoV-2 knocks out the vasodilatory modulation driven by ACE2 [7, 9], we indirectly documented the RAAS activation by monitoring [K+]plasma changes. Indeed, there is particular concern about hypokalemia in COVID-19, due to interaction of SARS-CoV-2 with RAAS [10]. According to [K+]plasma and BP variability, an up-regulation of aldosterone might be one of the fatal mechanisms leading to a negative prognosis. Aldosterone which is a potent arteriolar vasoconstrictor directly acts on salt and water retention as well as on inflammation [6]. Considering that a raising BP could mirror the systemic vasoconstriction due to ACE2 depletion, the increased ventilatory dead space (ΔA-aO₂) may be an expression of changes in pulmonary vessels tone leading to blood flow redistribution. Indeed, in stable condition, hypoxic pulmonary vasoconstriction is physiologically protective allowing a perfusion steering blood flow toward functionally preserved lung regions [11]. When COVID-19 reaches a certain stage, there is a disproportionate endothelial damage that disrupts pulmonary vasoregulation, promotes ventilation-perfusion mismatch (the primary cause of initial hypoxemia), and fosters thrombogenesis [12]. Overall, our evidence, that has to be further verified suggests that COVID-19 patients are less capable to counteract the progressive activation of the RAAS, then the Ang II/AT1R axis, via downregulation of ACE2. In group 1 a sort of physiological or pharmacological counterbalance restored the best possible status. In group 2, the extreme severity of the disease has led to worst outcome. The quicker the hemodynamic changes, the greater the severity of COVID-19 syndrome. While the results of the trial on recombinant-human-ACE2 are still awaited (NCT04335136), COVID-19 patients may benefit from known endothelial active agents, i.e. ACE-inhibitors, angiotensin II type-I receptor blockers or mineralcorticoid-receptor antagonists.
Figure legend:

Box plots of oxygen and inspiratory fraction of oxygen ratio (PaO2/FiO2; panel A), Alveolar-arterial oxygen gradient (ΔA-aO2; panel B), meanBP (BPmean; panel C), plasma potassium levels ([K+]plasma; panel D). Statistical significance was obtained through Mann-Whitney U Test comparing “Best status” with “Worst status”. *p<0.001.

Poon’s analysis of ΔA-aO2/meanBP (panel E; n= 137; slope= 6.666, R²=0.757; p< 0.0001) and Poon’s analysis of ΔA-aO2/meanBP according to [K+]plasma stratum (panel F). In panel F grey dots represent the group with [K+]plasma ≤ 3.8 mmol/L (n= 78; slope= 6.686, R²=0.774; p< 0.0001); white dots represent the group with [K+]plasma > 3.8 mmol/L (n= 59; slope= 4.491, R²=0.670; p< 0.0001).
References

1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.

2. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020: 367(6485): 1444-1448.

3. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005: 436(7047): 112-116.

4. Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P, Wang K, Han L, Duan Y, Zhao Z, Yang X, Xing L, Zhang P, Wang Z, Li R, Yu JJ, Wang X, Yang P. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep 2016: 6: 19840.

5. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circ Res 2020.

6. Guignabert C, de Man F, Lombes M. ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. Eur Respir J 2018: 51(6).

7. Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. Circulation 2020.

8. Poon CS. Analysis of linear and mildly nonlinear relationships using pooled subject data. J Appl Physiol (1985) 1988: 64(2): 854-859.

9. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020.

10. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr 2020: 14(3): 247-250.

11. Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A, Parlow LRG, Mewburn JD, Parlow JL, Archer SL. Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. Chest 2017: 151(1): 181-192.

12. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA 2020.
